Market Cap 6.60M
Revenue (ttm) 0.00
Net Income (ttm) -30.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 98,900
Avg Vol 217,297
Day's Range N/A - N/A
Shares Out 3.03M
Stochastic %K 50%
Beta 0.00
Analysts Strong Sell
Price Target $2.00

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 600 6438
Website: in8bio.com
Address:
350 5th Avenue, Suite 5330, New York, United States
Picklerinthekitchen
Picklerinthekitchen Jul. 7 at 11:05 AM
$INAB with such a low float INAB can easily dilute some shares out and raise quite enough money to continue onward and partner up as long as their trials continue to be positive.
0 · Reply
buymoremakemore
buymoremakemore Jul. 5 at 5:57 PM
$INAB TC BioPharm also focuses on gamma delta for AML. They trade on OTC. There are enough players in gamma delta T cell space that there needs to be something more special than a single Phase 2 ready oncology asset for partnerships and buyout. Especially something competitive like GBM which has increasingly impactful treatment options. Gene therapy companies too have good results for horrible diseases such as cancer and many have no investor/partner interest. Let's see how many quarters this goes with management saying a partnership is being worked on before this is under $1 again. Look at SGMO with Fabry Disease. And look at CMMB which is also low float but no partnership interest for PSC, a serious liver disease
1 · Reply
buymoremakemore
buymoremakemore Jul. 4 at 3:25 PM
$INAB This could be the next SGMO. Giving away IP for major illnesses basically for free to BP and saying partnerships are coming but have yet to.
1 · Reply
Olena
Olena Jul. 3 at 6:55 PM
$INAB any upcoming catalyst here? Besides low OS after RS and no cash on hands really
1 · Reply
DavidDayTrade
DavidDayTrade Jul. 3 at 4:06 PM
$INAB LOOKS LIKE IT'S READY TO GO
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 3 at 3:26 PM
$INAB $RGC Nonsense, sir! $TNXP is the next RGC. 👍 Praise be. It is hot as hell out my brother in Christ. I’m going to the pool. 🏊‍♂️
0 · Reply
Adamchristlover
Adamchristlover Jul. 3 at 3:23 PM
$INAB I think this will be the next $RGC . It will got to 50 this year.
1 · Reply
jacksparo
jacksparo Jul. 3 at 3:17 PM
$INAB I will keep a close eye on this for next week!!!
1 · Reply
3ARated
3ARated Jul. 3 at 3:13 PM
$INAB Looking good
0 · Reply
DavidDayTrade
DavidDayTrade Jul. 2 at 6:24 PM
$INAB it will come soon
0 · Reply
Latest News on INAB
IN8bio to Present at Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences


IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 7, 2023, 8:00 AM EST - 1 year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors


Picklerinthekitchen
Picklerinthekitchen Jul. 7 at 11:05 AM
$INAB with such a low float INAB can easily dilute some shares out and raise quite enough money to continue onward and partner up as long as their trials continue to be positive.
0 · Reply
buymoremakemore
buymoremakemore Jul. 5 at 5:57 PM
$INAB TC BioPharm also focuses on gamma delta for AML. They trade on OTC. There are enough players in gamma delta T cell space that there needs to be something more special than a single Phase 2 ready oncology asset for partnerships and buyout. Especially something competitive like GBM which has increasingly impactful treatment options. Gene therapy companies too have good results for horrible diseases such as cancer and many have no investor/partner interest. Let's see how many quarters this goes with management saying a partnership is being worked on before this is under $1 again. Look at SGMO with Fabry Disease. And look at CMMB which is also low float but no partnership interest for PSC, a serious liver disease
1 · Reply
buymoremakemore
buymoremakemore Jul. 4 at 3:25 PM
$INAB This could be the next SGMO. Giving away IP for major illnesses basically for free to BP and saying partnerships are coming but have yet to.
1 · Reply
Olena
Olena Jul. 3 at 6:55 PM
$INAB any upcoming catalyst here? Besides low OS after RS and no cash on hands really
1 · Reply
DavidDayTrade
DavidDayTrade Jul. 3 at 4:06 PM
$INAB LOOKS LIKE IT'S READY TO GO
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 3 at 3:26 PM
$INAB $RGC Nonsense, sir! $TNXP is the next RGC. 👍 Praise be. It is hot as hell out my brother in Christ. I’m going to the pool. 🏊‍♂️
0 · Reply
Adamchristlover
Adamchristlover Jul. 3 at 3:23 PM
$INAB I think this will be the next $RGC . It will got to 50 this year.
1 · Reply
jacksparo
jacksparo Jul. 3 at 3:17 PM
$INAB I will keep a close eye on this for next week!!!
1 · Reply
3ARated
3ARated Jul. 3 at 3:13 PM
$INAB Looking good
0 · Reply
DavidDayTrade
DavidDayTrade Jul. 2 at 6:24 PM
$INAB it will come soon
0 · Reply
jacksparo
jacksparo Jul. 2 at 5:49 PM
$INAB Maybe if not this week .. Next week?! It is getting closer to some action here!!
1 · Reply
Zackpedia
Zackpedia Jul. 1 at 10:46 PM
$INAB Exactly, hit Follow and subscribe to get my alerts on time and make money
0 · Reply
Florestan
Florestan Jul. 1 at 5:37 PM
$INAB raise money and save the programs. No other choice.
0 · Reply
Golibajje
Golibajje Jul. 1 at 3:48 PM
$PLRX hold it strongly! Over $4+ cash.. look at also $INAB.. only 2.7m public float.. treating difficult types of brain cancer.. can run like $LYRA over 500% when they report topline data anytime from now!! $GOSS $BGLC
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Jun. 30 at 8:22 PM
$INAB hanging tight !
0 · Reply
Ulong
Ulong Jun. 30 at 8:13 PM
$INAB "IN8bio, Inc. (NASDAQ:INAB) announced Monday that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires companies listed on the exchange to maintain a minimum bid price of at least $1.00 per share. The stock, currently trading at $2.13, has faced significant challenges, having declined over 90% in the past year according to InvestingPro data." ... https://www.investing.com/news/sec-filings/in8bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement-93CH-4116984
2 · Reply
Adarali
Adarali Jun. 30 at 4:51 PM
$INAB firstly CDT and than INAB..
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jun. 30 at 3:58 PM
$INAB You scumbags are so predictable and have no skills at all
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jun. 30 at 3:57 PM
$INAB Let’s go you A holes drop it to the $1’s already
0 · Reply
dogood
dogood Jun. 30 at 1:28 PM
$INAB can you run now multiple digits
0 · Reply
Adarali
Adarali Jun. 30 at 9:16 AM
$INAB look like VOR.. same..
0 · Reply
Ernesto62
Ernesto62 Jun. 28 at 7:58 AM
$INAB what will happen monday?
0 · Reply